October 9, 2023

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANK

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. CANCER CONTROL & PREVENTION

NRG-CC005/FORTE: Fast Facts (posted on CTSU)

NRG-CC005/FORTE: BBPS-ADR eBlast (posted on CTSU)

4. GYNECOLOGIC

GOG-0210: Reminder: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

NRG-CC008/SOROCk: There are 20 slots remaining for the 35- <42 age block of the BSO arm. Once these slots are filled, accrual will be temporarily held to allow the 35- <42 age block of the BLS arm to enroll the same number of patients. This age blocking is specified in the protocol to ensure equal distributions of patients because this is a non-randomized study. Please see protocol Section 14.5 for a description of the age blocking. 

NRG-GY031: The Biospecimen Collection and Submission Manual can be found on the NRG Oncology NRG-GY031 webpage during the Phase I portion of the trial. The manual will then be posted on the CTSU protocol page under Protocol Related Documents for the Phase II portion. This will be clarified in the protocol document with the next amendment.

5. HEAD & NECK

NRG-HN008

Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

RTOG 1216 - Sites in Canada only: The NOL and additional forms for amendment 9 are posted to CTSU. Please complete the CTSI, Protocol signature page and IB signature page and submit via the Regulatory submission portal. Please be sure to review the ICF memo included in this amendment’s documents.

6. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, November 8, 2023.

DRUG SAFETY UPDATES

Drug Safety updates have been issued for the following studies:

Call for Health Equity Fellowship Applications - Deadline extended to October 20, 2023

NRG Oncology is pleased to announce that it is partnering with the ASTRO and RTOG Foundation to offer a Health Equity Fellowship with an emphasis on radiation oncology. In addition, there is an opportunity for researchers involved in ovarian cancer prevention research, supported by the West Valley Ovarian Cancer Alliance (WVOCA). Applications are due October 20, 2023 (submit to Fellowships@NRGOncology.org). Please refer to the NRG Oncology website for more information.

REGISTER TODAY! The NRG Oncology LU008 Webinar

NRG Oncology Principal Investigator Charles Simone, MD, and Co-Principal Investigator John Heinzerling, MD will be hosting a webinar on their study, NRG-LU008. This webinar will feature presentations on select cases and how to think through, contour, and plan these cases. The webinar will be held on October 30, 2023 from 12-1 PM ET. Register here

Reminder! Federal Holiday Closure Announcement

The NRG Oncology Philadelphia East Operations and Buffalo SDMC offices are closed today, Monday, October 9, 2023, for the federal holiday. All other NRG offices will be open during regular business hours.

NRG Oncology is pleased to report the following scientific articles published during the previous week. Please follow the “Read More” link to access the full text online.

JOURNAL ARTICLES

Garden AS, Harris J, Eisbruch A, Chao KSC, Morrison WH, Harari PM, Swanson TA, Jones CU, Yom SS, Spencer SA, Scrimger R, Shenouda G, Shukla M, Lau HY, Mierzwa M, Torres-Saavedra P, Le QT. Final Report of NRG Oncology RTOG 0022: A Phase 1/2 Study of Conformal and Intensity Modulated Radiation for Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):333-340. doi: 10.1016/j.ijrobp.2023.02.057. Epub 2023 Mar 15. PMID: 36925074. Read More.

Kang J, Chowdhry AK, Pugh SL, Park JH. Integrating Artificial Intelligence and Machine Learning Into Cancer Clinical Trials. Semin Radiat Oncol. 2023 Oct;33(4):386-394. doi: 10.1016/j.semradonc.2023.06.004. PMID: 37684068. Read More.

Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):370-377. doi: 10.1016/j.ijrobp.2023.04.010. Epub 2023 May 2. PMID: 37137444. Read More.

Wong SJ, Torres-Saavedra PA, Saba NF, Shenouda G, Bumpous JM, Wallace RE, Chung CH, El-Naggar AK, Gwede CK, Burtness B, Tennant PA, Dunlap NE, Redman R, Stokes WA, Rudra S, Mell LK, Sacco AG, Spencer SA, Nabell L, Yao M, Cury FL, Mitchell DL, Jones CU, Firat S, Contessa JN, Galloway T, Currey A, Harris J, Curran WJ Jr, Le QT. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 Sep 28:e233809. doi: 10.1001/jamaoncol.2023.3809. Epub ahead of print. PMID: 37768670; PMCID: PMC10540060. Read More.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 11-15, 2023; Boston, MA

European Society for Medical Oncology (ESMO) Congress; Oct 20-24, 2023; Madrid, Spain

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2023; Seoul, South Korea

International Society for Quality-of-Life Research (ISOQOL); Oct 18-21, 2023; Calgary, AB

PA Breast Cancer Coalition (PBCC); Oct 17, 2023; Harrisburg, PA

Radiological Society of North America (RSNA); Nov 26-30, 2023; Chicago, IL

San Antonio Breast Cancer Symposium (SABCS); Dec 5-9, 2023; San Antonio, TX

Society for Immunotherapy of Cancer (SITC); Nov 3-5, 2023; San Diego, CA

Society for NeuroOncology (SNO); Nov 15-19, 2023; Vancouver, BC

Society for Urologic Oncology (SUO); Nov 28-Dec 1, 2023; Washington, DC

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Cancer Research (AACR) Annual Meeting; Apr 5-10, 2024; San Diego, CA; due to publications committee Nov 2, 2023; submission deadline Nov 16, 2023, 11:59 PM ET; LBA Jan 8, 2024, 11:59 PM ET

American Association for Thoracic Surgery (AATS) Annual Meeting; Apr 27-30, 2024; Toronto, ON; submission deadline Oct 16, 2023, 11:59 PM ET

American Head & Neck Society (AHNS) Annual Meeting; May 15-16, 2024; Chicago, IL; due to publications committee Oct 20, 2023; submission deadline Nov 3, 2023, 5:00 PM ET

American Society of Clinical Oncology (ASCO) GI; Jan 18-20, 2024; San Francisco, CA; LBA Oct 19, 2023, Noon ET

American Society of Clinical Oncology (ASCO) GU; Jan 25-27, 2024; San Francisco, CA; LBA Oct 26, 2023, Noon ET

American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting; Jun 1-4, 2024; Baltimore, MD; due to publications committee Oct 16, 2023; submission deadline Oct 29, 2023, 11:59 PM PT

Society of Gynecologic Oncology (SGO) Annual Meeting; Mar 16-18, 2024; San Diego, CA; submission deadline Oct 9, 2023